Merck and Samsung Bioepis Announce Approval of BRENZYS (Etanercept), a Biosimilar of Enbrel, in Korea

Merck and Samsung Bioepis Announce Approval of BRENZYS™ (Etanercept),
a Biosimilar of Enbrel, in Korea

 First Product from Global Partnership to Deliver High-Quality Biosimilars
to Help Meet Needs of Patients and Healthcare Systems Worldwide

 KENILWORTH, N.J., and SEOUL, South Korea, Sept. 8, 2015 – Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd. today announced the approval of BRENZYS™ (etanercept), a biosimilar of the immunology medicine Enbrel, by the Ministry of Food and Drug Safety (MFDS) in Korea. BRENZYS is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis (non-radiographic axial spondyloarthritis and ankylosing spondylitis) and psoriasis in adult patients (age 18 years and older)

Republicado por:RM Consult